ArticleTranslational cancer research2025
Pan-cancer evaluation of ABAT as an emerging biomarker and its implication in lung adenocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of γ-aminobutyric acid and its receptor in metabolic reprogramming and tumor progression.Biochemistry and biophysics reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: 4-aminobutyric acid aminotransferase (ABAT) is a pivotal enzyme for mitochondrial metabolism and central nervous system homeostasis, with known links to neurotransmitter regulation and mental illnesses. However, its role in cancer remains understudied. This study aims to comprehensively evaluate ABAT's pan-cancer landscape-including gene expression, diagnostic-prognostic value, epigenetic modifications, immune infiltration, and drug sensitivity-and validate its functional role in lung adenocarcinoma (LUAD). Methods: Using multi-omics data from TCGA (The Cancer Genome Atlas), HPA (Human Protein Atlas), UALCAN (University of Alabama at Birmingham Library Cancer Analysis Portal), TIMER2.0 (Tumor IMmune Estimation Resource 2.0), and other databases, we conducted bioinformatics analyses to characterize ABAT across 33 cancer types. In vitro validation involved quantitative real-time polymerase chain reaction (qRT-PCR) and transwell assays to assess ABAT expression, migration, and invasion in LUAD tissues and cell lines. Results: ABAT was significantly underexpressed in 11 cancers [e.g., kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), LUAD] and overexpressed in [breast invasive carcinoma (BRCA)/pheochromocytoma/paraganglioma (PCPG)], with expression correlating with tumor staging (e.g., stage III LUAD). It exhibited high diagnostic accuracy [area under curve (AUC) >0.8] in 5 cancers [cholangiocarcinoma (CHOL), kidney chromophobe carcinoma (KICH)] and predicted poor prognosis in KIRC, LUAD, etc. Promoter hypermethylation negatively correlated with ABAT expression in most cancers. ABAT associated with CD8 Conclusions: ABAT shows expression heterogeneity in pan-cancer, linking to diagnosis, prognosis, immune microenvironment, and drug response. Its tumor-suppressive role in LUAD highlights ABAT as a potential biomarker and therapeutic target for precision oncology, warranting further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.